




Instance: composition-en-a5f47c93f2a2eb5b88e9129e2aa9f3b9
InstanceOf: CompositionUvEpi
Title: "Composition for esmya Package Leaflet"
Description:  "Composition for esmya Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf4f0f7a4cf4a4d48ad9217202084f497)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - esmya"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Esmya is and what it is used for </li>
<li>What you need to know before you take Esmya </li>
<li>How to take Esmya </li>
<li>Possible side effects </li>
<li>How to store Esmya </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What esmya is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What esmya is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Esmya contains the active substance ulipristal acetate. It is used to treat moderate to severe symptoms 
of uterine fibroids (commonly known as myomas), which are non-cancerous tumours of the uterus 
(womb).<br />
Esmya is used in adult women (over 18 years of age) before they reach the menopause. </p>
<p>In some women, uterine fibroids may cause heavy menstrual bleeding (your  period ), pelvic pain 
(discomfort in the belly) and create pressure on other organs. </p>
<p>This medicine acts by modifying the activity of progesterone, a naturally occuring hormone in the 
body. It is used for long term treatment of your fibroids to reduce their size, to stop or reduce bleeding 
and to increase your red blood cell count. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take esmya"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take esmya"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You should know that most women have no menstrual bleeding (period) during the treatment and for a 
few weeks afterwards.  </p>
<p>Do not take Esmya 
- if you are allergic to ulipristal acetate or any of the other ingredients of Esmya (listed in 
section 6). 
- if you have an underlying hepatic disorder. 
- if you are pregnant or if you are breastfeeding. 
- if you have vaginal bleeding not caused by uterine fibroids. 
- if you have cancer of the uterus (womb), cervix (the neck of the womb), ovary or breast. </p>
<p>Warnings and precautions 
- Before you start treatment with Esmya blood tests will be undertaken to find out how well your 
liver is working. Depending on the result of these tests your doctor will decide if treatment with 
Esmya is suitable for you. These tests will be repeated monthly for the first 2 treatment courses. 
For further treatment courses, your liver will be checked once before each new treatment course 
and if you experience any of the symptoms described below. In addition, an additional check of 
your liver 2-4 weeks after your treatment has stopped should be done.<br />
If during the treatment you experience any liver related signs such as feeling of being sick 
(nausea or vomiting), fatigue, severe tiredness, jaundice (yellowing of the eyes or skin), dark 
urine, itching or upper stomach ache, you should stop treatment and immediately contact a 
doctor, who will check the functioning of your liver and decide if you can continue the 
treatment. 
- If you are currently taking hormonal contraception (for example birth control pills) (see  Other 
medicines and Esmya ) you should use an alternative reliable barrier contraceptive method 
(such as a condom) while taking Esmya. 
- If you have liver or kidney disease tell your doctor or pharmacist before taking Esmya. 
- If you suffer from severe asthma, treatment with Esmya may not be suitable for you. You 
should discuss this with your doctor. </p>
<p>Treatment with Esmya usually leads to a significant reduction or may even stop your menstrual 
bleeding (your  period ) within the first 10 days of treatment. However, if you continue to experience 
excessive bleeding tell your doctor. </p>
<p>Your period should generally return within 4 weeks after treatment with Esmya is stopped. The lining 
of the uterus may thicken or change as a result of taking Esmya. These changes return to normal after 
treatment is stopped and your periods restart. </p>
<p>Children and adolescents 
Esmya should not be taken by children under 18 years of age since safety and efficacy of ulipristal 
acetate has not been established in this age group. </p>
<p>Other medicines and Esmya 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Tell your doctor or pharmacist if you are taking any of the medicines listed below, as these medicines 
can affect Esmya or be affected by Esmya:</p>
<ul>
<li>Certain medicines which are used to treat the heart (e.g. digoxin). </li>
<li>Certain medicines used to prevent strokes and blood clots (e.g. dabigatran etexilate). </li>
<li>Certain medicines used to treat epilepsy (e.g. phenytoin, fosphenytoin, phenobarbital, 
carbamazepine, oxcarbazepine, primidone). </li>
<li>Certain medicines used to treat HIV infection (e.g. ritonavir, efavirenz, nevirapine). </li>
<li>Medicines used to treat certain bacterial infections (e.g. rifampicin, telithromycin, 
clarithromycin, erythromycin, rifabutin). </li>
<li>Certain medicines to treat fungal infections (e.g. ketoconazole (except shampoo), itraconazole). </li>
<li>Herbal remedies containing St John s wort (Hypericum perforatum) used for depression or 
anxiety. </li>
<li>Certain medicines used to treat depression (e.g. nefazodone). </li>
<li>Certain medicines used to treat hypertension (e.g. verapamil). </li>
</ul>
<p>Esmya is likely to make some hormonal contraceptives less effective. In addition, hormonal 
contraceptives and progestagens (e.g. norethindrone or levonorgestrel) are also likely to make Esmya 
less effective. Therefore, hormonal contraceptives are not recommended and you should use an 
alternative reliable barrier contraceptive method, such as a condom, during Esmya treatment. </p>
<p>Esmya with food and drink 
You should avoid drinking grapefruit juice while on treatment with Esmya. </p>
<p>Pregnancy and breastfeeding 
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. 
Do not take Esmya if you are pregnant. Treatment whilst pregnant might affect your pregnancy (it is 
not known if Esmya might harm your baby or whether can cause miscarriage). If you do become 
pregnant during Esmya treatment, you should stop taking Esmya immediately and contact your doctor 
or pharmacist. </p>
<p>Esmya is likely to make some hormonal contraceptives less effective (see  Other medicines and 
Esmya ). 
Esmya passes into the breast milk. Therefore, do not breast-feed your baby while taking Esmya. </p>
<p>Driving and using machines 
Esmya may cause mild dizziness (see section 4  Possible side effects ). Do not drive or use machines 
if you experience these symptoms. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take esmya"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take esmya"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. 
The recommended dose is one 5 mg tablet per day, for treatment courses of up to 3 months each. If 
you have been prescribed several courses of Esmya 3-month treatment, you should start each course at 
the earliest during the second menstrual period following the previous treatment completion. 
You should always start taking Esmya within the first week of your menstrual period. 
The tablet should be swallowed with water and may be taken with or without food. </p>
<p>If you take more Esmya than you should 
Experience with Esmya when several doses are taken at once is limited. There have been no reports of 
serious harmful effects from taking several doses of this medicine at once. You should nonetheless ask 
your doctor or pharmacist for advice if you take more Esmya than you should. </p>
<p>If you forget to take Esmya 
If you miss a dose by less than 12 hours, take it as soon as you remember. If you miss a dose by more 
than 12 hours, skip the missed tablet and take only a single tablet as usual. Do not take a double dose 
to make up for a forgotten tablet. </p>
<p>If you stop taking Esmya 
Esmya is to be taken daily during treatment courses of up to 3 months continuously. During each 
course of treatment, do not stop taking your tablets without the advice of your doctor even if you feel 
better, as symptoms may re-occur later. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Stop using Esmya and immediately contact a doctor if you experience any of the following symptoms:</p>
<ul>
<li>swelling of face, tongue or throat; difficulty swallowing; hives and breathing difficulties. These 
are possible symptoms of angioedema (frequency not known). </li>
<li>nausea or vomiting, severe tiredness, jaundice (yellowing of the eyes or skin), dark urine, itching 
or upper stomach ache. These symptoms may be signs of liver injury (frequency not known), 
which in a small number of cases led to liver transplantation. See also section 2 Warnings and 
precautions.  </li>
</ul>
<p>Very common (may affect more than 1 in 10 people) side effects:</p>
<ul>
<li>reduction or absence of menstrual bleeding (amenorrhea) </li>
<li>thickening of the lining of the womb (endometrial thickening). </li>
</ul>
<p>Common (may affect up to 1 in 10 people) side effects:</p>
<ul>
<li>headache </li>
<li>spinning sensation (vertigo) </li>
<li>stomach ache, feeling sick (nausea) </li>
<li>acne </li>
<li>muscle and bone (musculoskeletal) pain </li>
<li>sac of fluid within the ovaries (ovarian cyst), breast tenderness/pain, lower abdominal (pelvic) 
pain, hot flushes </li>
<li>tiredness (fatigue) </li>
<li>weight increase. </li>
</ul>
<p>Uncommon (may affect up to 1 in 100 people) side effects:</p>
<ul>
<li>drug allergy </li>
<li>anxiety </li>
<li>mood swings </li>
<li>dizziness </li>
<li>dry mouth, constipation </li>
<li>hair loss, dry skin, increased sweating </li>
<li>back pain </li>
<li>leakage of urine </li>
<li>bleeding from the womb (uterine bleeding), vaginal discharge, abnormal vaginal bleeding, 
breast discomfort </li>
<li>swelling due to fluid retention (oedema) </li>
<li>extreme tiredness (asthenia) </li>
<li>increase in blood cholesterol seen in blood tests, increase in blood fats (triglycerides) seen in 
blood tests. </li>
</ul>
<p>Rare (may affect up to 1 in 1,000 people) side effects:</p>
<ul>
<li>nosebleed </li>
<li>indigestion, bloating </li>
<li>break of sac of fluid within the ovaries (ovarian cyst ruptured) </li>
<li>breast swelling. </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store esmya"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store esmya"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and on the blister after 
EXP. The expiry date refers to the last day of that month. </p>
<p>Keep the blister in the outer carton in order to protect from light. </p>
<p>Do not throw away via wastewater or household waste. Ask your pharmacist how to throw away 
medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Esmya contains 
- The active substance is ulipristal acetate. One tablet contains 5 mg of ulipristal acetate. 
- The other ingredients are microcrystalline cellulose, mannitol, croscarmellose sodium, talc and 
magnesium stearate. </p>
<p>What Esmya looks like and contents of the pack 
Esmya is white to off-white, round curved tablet of 7 mm engraved with code  ES5  on one face. 
It is available in Alu/PVC/PE/PVDC blisters in cartons containing 28, 30 and 84 tablets or 
Alu/PVC/PVDC blisters in cartons containing 28 and 84 tablets. 
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Gedeon Richter Plc. 
Gy mr i  t 19-21. 1103 Budapest 
Hungary </p>
<p>Manufacturer 
Cenexi 
17 rue de Pontoise 
F-95520 Osny 
France </p>
<p>Gedeon Richter Plc. 
Gy mr i  t 19-21. 1103 Budapest 
Hungary </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information<br />
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-a5f47c93f2a2eb5b88e9129e2aa9f3b9
InstanceOf: CompositionUvEpi
Title: "Composition for esmya Package Leaflet"
Description:  "Composition for esmya Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf4f0f7a4cf4a4d48ad9217202084f497)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - esmya"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Se den nyeste indlægsseddel på www.indlaegsseddel.dk </p>         </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Esmya 
3. Sådan skal du tage Esmya 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What esmya is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What esmya is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Esmya indeholder det aktive stof ulipristalacetat. Det bruges til at behandle moderate til svære 
symptomer på fibromer i uterus (kaldes også muskelknuder i livmoderen eller myomer), der er 
godartede tumorer i uterus (livmoderen). 
Esmya anvendes til voksne kvinder (over 18 år), før de kommer i overgangsalderen. </p>
<p>Uterusfibromer kan hos nogle kvinder give kraftig menstruationsblødning, bækkensmerter 
(mavegener) og trykke på andre organer. </p>
<p>Dette lægemiddel virker ved at ændre progesterons aktivitet. Progesteron er et naturligt forekommende 
hormon i kroppen. Esmya anvendes til langvarig behandling af dine fibromer for at reducere deres 
størrelse, for at stoppe eller reducere blødning og for at øge antallet af røde blodlegemer. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take esmya"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take esmya"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du skal vide, at de fleste kvinder ikke har menstruation under behandlingen og i nogle få uger 
derefter. </p>
<p>Tag ikke Esmya 
- hvis du er allergisk over for ulipristalacetat eller et af de øvrige indholdsstoffer (angivet i pkt. 
6).<br />
- hvis du har en leversygdom. 
- hvis du er gravid, eller hvis du ammer. 
- hvis du har blødning fra skeden, der ikke skyldes uterusfibromer. 
- hvis du har livmoder-, livmoderhals-, brystkræft eller kræft i æggestokkene. </p>
<p>Advarsler og forsigtighedsregler 
- Før du påbegynder behandling med Esmya, bliver der taget blodprøver for at finde ud af, hvor 
godt din lever fungerer. Alt efter resultatet af disse prøver beslutter din læge, om behandling 
med Esmya er egnet til dig. Prøverne gentages hver måned under de 2 første behandlingsforløb. 
Ved efterfølgende behandlingsforløb bliver din lever kontrolleret én gang før hvert nye 
behandlingsforløb, og hvis du oplever et eller flere af de symptomer, som er beskrevet nedenfor. 
Desuden bør leverfunktionen kontrolleres 2-4 uger efter, at behandlingen er ophørt.<br />
Hvis du under behandlingen oplever nogen tegn, der har forbindelse til leveren, f.eks. kvalme, 
opkastning, træthed, ekstrem træthed, gulsot (gulfarvning af øjne eller hud), mørkfarvet urin, 
kløe eller smerter øverst i maveregionen, skal du afbryde behandlingen og straks søge læge, 
som kontrollerer leverfunktionen og beslutter, om du kan fortsætte med behandlingen. 
- Hvis du i øjeblikket anvender hormonprævention (f.eks. p-piller) (se "Brug af anden medicin 
sammen med Esmya), bør du også bruge en anden pålidelig barriere-prævention (f.eks. et 
kondom), mens du tager Esmya. 
- Hvis du har en lever- eller nyresygdom, skal du fortælle det til lægen eller på apoteket, før du 
tager Esmya. 
- Hvis du lider af svær astma, er behandling med Esmya måske ikke egnet til dig. Du bør tale om 
dette med din læge. </p>
<p>Behandling med Esmya medfører normalt en væsentlig reduktion eller stopper måske også din 
menstruation i løbet af de første 10 dages behandling. Hvis den kraftige blødning fortsætter, skal du 
informere deres læge. </p>
<p>Din menstruation bør normalt vende tilbage i løbet af 4 uger, efter behandling med Esmya er stoppet. 
Livmoderslimhinden kan blive tykkere eller ændre sig, når du tager Esmya. Disse ændringer 
forsvinder, efter at behandlingen er stoppet, og din menstruation starter igen. </p>
<p>Børn og unge 
Esmya bør ikke anvendes til børn under 18 år, da ulipristalacetats sikkerhed og virkning ikke er 
klarlagt for denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med Esmya 
Fortæl altid lægen eller på apoteket, hvis du tager anden medicin eller har gjort det for nylig. Dette 
gælder også medicin, som ikke er købt på recept, f.eks. naturlægemidler og vitaminer og mineraler. </p>
<p>Fortæl det til lægen eller på apoteket, hvis du tager nogen af de lægemidler, der er nævnt herunder, 
eftersom disse lægemidler kan påvirke Esmya eller blive påvirket af Esmya:</p>
<ul>
<li>Visse lægemidler mod hjertesygdomme (f.eks. digoxin). </li>
<li>Visse lægemidler, der bruges for at forebygge slagtilfælde og blodpropper (f.eks. 
dabigatranetexilat). </li>
<li>Visse lægemidler mod epilepsi (f.eks. phenytoin, fosphenytoin, phenobarbital, carbamazepin, 
oxcarbazepin, primidon). </li>
<li>Visse lægemidler mod hiv-infektion (f.eks. ritonavir, efavirenz, nevirapin). </li>
<li>Lægemidler mod visse bakterieinfektioner (f.eks. rifampicin, telithromycin, clarithromycin, 
erythromycin, rifabutin). </li>
<li>Visse lægemidler mod svampeinfektioner (f.eks. ketoconazol (undtagen shampoo), itraconazol). </li>
<li>Naturlægemidler med perikon (Hypericum perforatum), der anvendes mod depression eller angst. </li>
<li>Visse lægemidler mod depression (f.eks. nefazodon). </li>
<li>Visse lægemidler mod for højt blodtryk (f.eks. verapamil). </li>
</ul>
<p>Esmya vil sandsynligvis nedsætte virkningen af visse hormonelle præventionsmidler. Desuden vil 
hormonelle præventionsmidler (f.eks. norethindron eller levonorgestrel) også sandsynligvis nedsætte 
virkningen af Esmya. Derfor frarådes brug af hormonelle præventionsmidler, og du bør bruge en 
anden pålidelig barriere-prævention (f.eks. et kondom), når du er i behandling med Esmya. </p>
<p>Brug af Esmya sammen med mad og drikke 
Du skal undgå at drikke grapefrugtjuice, når du tager Esmya. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Du må ikke tage Esmya, hvis du er gravid. Behandling under graviditet kan påvirke graviditeten (det 
vides ikke, om Esmya kan skade barnet, eller om det kan forårsage abort). Hvis du bliver gravid, mens 
du er i behandling med Esmya, skal du straks holde op med at tage Esmya og kontakte din læge eller 
apoteket. </p>
<p>Esmya vil sandsynligvis nedsætte virkningen af visse hormonelle præventionsmidler (se "Brug af 
anden medicin sammen med Esmya). 
Esmya går over i mælken. Du må derfor ikke amme dit barn, når du tager Esmya. </p>
<p>Trafik- og arbejdssikkerhed 
Esmya kan forårsage let svimmelhed (se pkt. 4 "Bivirkninger"). Kør ikke bil eller motorcykel, og lad 
være med at arbejde med værktøj eller maskiner, hvis du oplever disse symptomer. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take esmya"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take esmya"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid dette lægemiddel nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller på 
apoteket. 
Den sædvanlige dosis er én 5 mg tablet om dagen i behandlingsforløb på op til 3 måneder. Hvis du har 
fået ordineret flere 3-måneders behandlingsforløb med Esmya, må du tidligst starte hvert forløb i den 
anden menstruationsperiode efter afslutning af det foregående behandlingsforløb. 
Du skal altid starte med at tage Esmya i løbet af menstruationens første uge. 
Tabletten skal synkes med vand og kan tages sammen med et måltid eller mellem måltiderne. </p>
<p>Hvis du har taget for meget Esmya 
Der er begrænset erfaring med Esmya, når der tages flere doser på én gang. Der er ikke rapporteret om 
alvorlige, skadelige virkninger efter indtagelse af flere doser af dette lægemiddel på én gang. Ikke 
desto mindre skal du spørge lægen eller apoteket til råds, hvis du tager for meget Esmya.  </p>
<p>Hvis du har glemt at tage Esmya 
Hvis du glemmer at tage en dosis i mindre end 12 timer, skal du tage den hurtigst muligt. Hvis du 
glemmer en dosis i mere end 12 timer, skal du springe den glemte tablet over og kun tage en enkelt 
tablet som normalt. Du må ikke tage en dobbeltdosis som erstatning for den glemte tablet. </p>
<p>Hvis du holder op med at tage Esmya 
Esmya skal tages dagligt i behandlingsforløb på op til 3 måneder uden afbrydelse. I hvert 
behandlingsforløb må du ikke holde op med at tage tabletterne, medmindre din læge beder dig om det, 
heller ikke selvom du har det bedre, eftersom symptomerne kan komme igen senere.  </p>
<p>Spørg lægen eller på apoteket, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Stop med at bruge Esmya, og kontakt straks en læge, hvis du oplever et eller flere af følgende 
symptomer:</p>
<ul>
<li>hævelse af ansigt, tunge eller svælg, synkebesvær, nældefeber og vejrtrækningsbesvær. Disse er 
mulige symptomer på angioødem (hyppighed ikke kendt). </li>
<li>Kvalme eller opkastning, ekstrem træthed, gulsot (gulfarvning af øjne eller hud), mørkfarvet 
urin, kløe eller smerter øverst i maveregionen. Disse symptomer kan være tegn på leverskade 
(hyppighed ikke kendt), som i få tilfælde har medført levertransplantation. Se også punkt 2 
Advarsler og forsigtighedsregler. </li>
</ul>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer) 
- Reduktion eller udeblivelse af menstruation (amenorré).<br />
- Fortykkelse af livmoderslimhinden (fortykket endometrium).  </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer) 
- Hovedpine. 
- Fornemmelse af at snurre rundt (vertigo). 
- Mavesmerter, kvalme. 
- Akne. 
- Smerter i muskler og knogler (muskuloskeletale smerter). 
Væskefyldt blære på æggestokkene (ovariecyste), brystømhed/-smerter, bækkensmerter, hedeture. 
- Træthed. 
- Vægtøgning. </p>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer) 
- Lægemiddelallergi. 
- Angst. 
- Humørsvingninger. 
- Svimmelhed. 
- Mundtørhed, forstoppelse. 
- Hårtab, tør hud, svedtendens. 
- Rygsmerter. 
- Urinlækage. 
- Blødning fra livmoderen (uterinblødning), udflåd fra skeden, unormal blødning fra skeden. 
- Gener i brystet. 
- Hævelse pga. væskeophobning (ødem). 
- Ekstrem træthed (asteni). 
- Forhøjet kolesterol i blodet (ses i blodprøver), forhøjede triglycerider (fedt i blodet - ses i 
blodprøver). </p>
<p>Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1.000 personer):</p>
<ul>
<li>Næseblødning. </li>
<li>Fordøjelsesbesvær, oppustethed. </li>
<li>Brud på væskesæk i æggestokkene (ovariecyste). </li>
<li>Hævelse af bryst. </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apoteket. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks 
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store esmya"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store esmya"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar dette lægemiddel utilgængeligt for børn </p>
<p>Brug ikke dette lægemiddel efter den udløbsdato, der står på pakningen. Udløbsdatoen er den sidste 
dag i den nævnte måned. </p>
<p>Opbevar blisteret i den ydre karton for at beskytte mod lys. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Esmya indeholder:</p>
<ul>
<li>Aktivt stof: Ulipristalacetat. En tablet indeholder 5 mg ulipristalacetat. </li>
<li>Øvrige indholdsstoffer: Mikrokrystallinsk cellulose, mannitol, croscarmellosenatrium, talcum 
og magnesiumstearat. </li>
</ul>
<p>Udseende og pakningsstørrelser 
Esmya er en hvid til næsten hvid, rund, buet tablet på 7 mm præget med koden "ES5" på den ene side. 
Det fås i alu/PVC/PE/PVDC blister i kartoner a 28, 30 og 84 tabletter eller alu/PVC/PVDC blister i 
kartoner a 28 og 84 tabletter. 
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Gedeon Richter Plc. 
Gyömrői út 19-21. 1103 Budapest 
Ungarn </p>
<p>Fremstiller 
Cenexi 
17, rue de Pontoise 
F-95520 Osny 
Frankrig </p>
<p>Gedeon Richter Plc. 
Gyömrői út 19-21. 1103 Budapest 
Ungarn </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-a5f47c93f2a2eb5b88e9129e2aa9f3b9
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for esmya Package Leaflet for language en"
Description: "ePI document Bundle for esmya Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-a5f47c93f2a2eb5b88e9129e2aa9f3b9"
* entry[0].resource = composition-en-a5f47c93f2a2eb5b88e9129e2aa9f3b9

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa5f47c93f2a2eb5b88e9129e2aa9f3b9"
* entry[=].resource = mpa5f47c93f2a2eb5b88e9129e2aa9f3b9
                            
                    
Instance: bundlepackageleaflet-da-a5f47c93f2a2eb5b88e9129e2aa9f3b9
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for esmya Package Leaflet for language da"
Description: "ePI document Bundle for esmya Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-a5f47c93f2a2eb5b88e9129e2aa9f3b9"
* entry[0].resource = composition-da-a5f47c93f2a2eb5b88e9129e2aa9f3b9

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa5f47c93f2a2eb5b88e9129e2aa9f3b9"
* entry[=].resource = mpa5f47c93f2a2eb5b88e9129e2aa9f3b9
                            
                    



Instance: mpa5f47c93f2a2eb5b88e9129e2aa9f3b9
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product esmya"
Description: "esmya"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/12/750/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "esmya"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: a5f47c93f2a2eb5b88e9129e2aa9f3b9ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "esmya"

* status = #current
* mode = #working

* title = "List of all ePIs associated with esmya"

* subject = Reference(mpf4f0f7a4cf4a4d48ad9217202084f497)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#esmya "esmya"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-a5f47c93f2a2eb5b88e9129e2aa9f3b9) // esmya en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-a5f47c93f2a2eb5b88e9129e2aa9f3b9) // esmya da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-a5f47c93f2a2eb5b88e9129e2aa9f3b9
InstanceOf: List

* insert a5f47c93f2a2eb5b88e9129e2aa9f3b9ListRuleset
    